## 4 Therapeutic Potential and Applications of p-C
p-C can also reduce ulcerations, lesion scores, and diarrhea in colonic inflammation, and has been shown to enhance immunostaining by affecting the expression of the suppressor of cytokine signaling 3. Specifically, it has been shown to reduce IL-16 and TNF-\(\alpha\) and maintain IL-10 [108]. Furthermore, in experiments using HCT116 and _HepG2 cells_, _O. onites_ essential oil, carvacrol, and p-C were used at a concentration of 400 ug/mL. The results of cell experiments using the MTT assay and DCFH-DA method confirmed that p-C from _O. onites_ essential oil can be considered as a drug candidate for cancer treatment [109]. As such, the potential therapeutic value of p-C is shown in Table 2. \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Subjects** & **Treatment Strategies** & **Setting** & **Findings** & **References** \\ \hline \multirow{4}{*}{_Candida albicans_ and _Candida glabrata_ (antimicrobial strains) & \multirow{4}{*}{Electrospinning of p-C _candida glabrata_ (antimicrobial strains) _Landing of p-C into nanofibers _Landing of p-C into nanofibers _Landing of p-C into nanofibers based on gellan and PVA for use as wound dressing material _O. onites_ essential oil can be considered as a drug candidate for cancer treatment [109]. As such, the potential therapeutic value of p-C is shown in Table 2. The use of p-C as a potential therapeutic agent, with a focus on clinical examples. & In vitro: Characterize nanofibers & \\  & & & nanofibers & \\ \cline{1-1} \cline{3-4} \multirow{4}{*}{_Candida albicans_ and _Candida glabrata_ (antimicrobial strains) _NIH3T3 cell line (cytotoxicity test) & \multirow{4}{*}{Electrospinning of p-C _candida glabrata_ (antimicrobial strains) _Landing of p-C into nanofibers based on gellan and PVA for use as wound dressing material _O. onites_ essential oil can be considered as a drug candidate for cancer treatment [109]. As such, the potential therapeutic value of p-C is shown in Table 2. & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: The use of p-C as a potential therapeutic agent, with a focus on clinical examples. \begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Subjects** & **Treatment Strategies** & **Setting** & **Findings** & **References** \\ \hline  & & & & p-C significantly reduced \\  & & & ethanol-induced gastric lesions, \\  & & & increased mucus secretion, \\  & & & & increased pH, and decreased \\  & Normal vs. ulcer control: & Absolute ethanol-induced & ulcer area and edema \\  & Oral administration of & acute gastric mucosal & SOD, CAT, and PGE2 activities \\  & 0.5\% CMC & hemorrhagic lesion model & increased and MDA levels \\
30 _Sprague Dawley rats_ & Baseline: 20 mg/kg & Rats were sacrificed after & decreased \\  & & & the experiment to perform & Increased PAS staining \\  & Experimental group: & gastric mucosal and & intensity, increased HSP \\  & 30 mg/kg and 60 mg/kg & inflammation-related & 70 expression, decreased Bax \\  & p-cymene orally & analyses & expression, decreased TNF-\(\alpha\) \\  & & & and IL-6, and increased IL-10 \\  & & & No signs of toxicity at a 500 \\  & & & mg/kg dose and enhanced \\  & & & gastric mucosal protection \\ \hline  & & & \\ _HeLa_ cells (cervical & [(n6-p-cymene)RuCl2L] & & \\ cancer cells) & (L = 4-cyanopyridine, & & \\ _MCF_-7 cells (breast & 2-aminophen, & & \\ cancer cells) BGM cells & 4-aminophen, & & \\ (healthy monkey & pyridazine) and [(n6-p- & \\ kidney skin cells) & cymene)RuCl2L]PF6 & & \\  & (L = cyanopyridine, & & \\  & & 2-aminophen) & \\ \hline  & & & \\ \begin{tabular}{c} Ruthenium(II) \\ complexes: \\ \end{tabular}  & \begin{tabular}{c} Replacing the metal \\ center of plexcatin 2, the \\ most promising oral \\ anticancer drug, with Ru, \\ Os, Rh, and Ir \\ \end{tabular}  & \begin{tabular}{c} Solvent: Ligand exchange \\ reaction in aqueous \\ solution \\ Analytical methods: 1H \\ NMR spectra, amino acid \\ reactions, and in vitro \\ experiments to assess \\ anticancer activity \\ \end{tabular}  &